首页 > 最新文献

Cardiovascular and Hematological Agents in Medicinal Chemistry最新文献

英文 中文
Antihyperglycemic and Antidyslipidemic Activities of the Aqueous Salvia hispanica Extract in Diabetic Rat. 丹参水提物对糖尿病大鼠的降血糖和降血脂作用。
Q2 Medicine Pub Date : 2022-01-01 DOI: 10.2174/1871525719666210112154340
El-Ouady Fadwa, Ayoub Amssayef, Mohamed Eddouks

Aims: The study targeted to evaluate the antihyperglycemic activity of Salvia hispanica.

Background: Salvia hispanica L. (Lamiaceae) is a medicinal plant with many beneficial properties on human health.

Objective: This objective of the study was to investigate the antihyperglycemic effect of the aqueous extract of Salvia hispanica (S. hispanica) seeds and its capacity to improve lipid profile in normal and STZ-induced diabetic rats.

Material and methods: The seed aqueous extract of S. hispanica (SHSAE) at a dose of 100 mg/kg was administered orally in normal and diabetic rats. The effect of oral SHSAE treatment on blood glucose and lipid levels during 15 days was assessed in normal and streptozotocin-induced diabetic rats. The oral glucose tolerance test (OGTT) was carried out. The antioxidant activity of SHSAE was also examined.

Results: The decrease of glycemia in rats following the administration of the plant extract suggested that the studied extract possesses antidiabetic effect. The extract of S. hispanica produced hypolipidemic effect with a significant lowering effect on plasma total cholesterol levels and increased on HDL-cholesterol levels. SHSAE was also able to enhance glucose tolerance using OGTT. Moreover, SHSAE possesses a potential antioxidant effect in vitro.

Conclusion: In conclusion, this study demonstrates the antihyperglycemic and antilipidemic effects of SHSAE in rats.

目的:研究丹参的降血糖作用。背景:鼠尾草(Salvia hispanica L.)是一种对人体健康有益的药用植物。目的:研究鼠尾草种子水提物对正常及stz诱导的糖尿病大鼠的降血糖作用及其对血脂的改善作用。材料与方法:以100 mg/kg的剂量给药于正常大鼠和糖尿病大鼠。观察口服SHSAE对正常和链脲佐菌素诱导的糖尿病大鼠15 d血糖和血脂水平的影响。进行口服糖耐量试验(OGTT)。研究了SHSAE的抗氧化活性。结果:给药后大鼠血糖明显下降,提示所研究的植物提取物具有抗糖尿病作用。西班牙花提取物具有降血脂作用,显著降低血浆总胆固醇水平,提高高密度脂蛋白胆固醇水平。SHSAE还能够通过OGTT提高葡萄糖耐量。此外,SHSAE在体外具有潜在的抗氧化作用。结论:本研究证实了SHSAE对大鼠的降糖、降脂作用。
{"title":"Antihyperglycemic and Antidyslipidemic Activities of the <i>Aqueous Salvia hispanica</i> Extract in Diabetic Rat.","authors":"El-Ouady Fadwa,&nbsp;Ayoub Amssayef,&nbsp;Mohamed Eddouks","doi":"10.2174/1871525719666210112154340","DOIUrl":"https://doi.org/10.2174/1871525719666210112154340","url":null,"abstract":"<p><strong>Aims: </strong>The study targeted to evaluate the antihyperglycemic activity of Salvia hispanica.</p><p><strong>Background: </strong>Salvia hispanica L. (Lamiaceae) is a medicinal plant with many beneficial properties on human health.</p><p><strong>Objective: </strong>This objective of the study was to investigate the antihyperglycemic effect of the aqueous extract of Salvia hispanica (S. hispanica) seeds and its capacity to improve lipid profile in normal and STZ-induced diabetic rats.</p><p><strong>Material and methods: </strong>The seed aqueous extract of S. hispanica (SHSAE) at a dose of 100 mg/kg was administered orally in normal and diabetic rats. The effect of oral SHSAE treatment on blood glucose and lipid levels during 15 days was assessed in normal and streptozotocin-induced diabetic rats. The oral glucose tolerance test (OGTT) was carried out. The antioxidant activity of SHSAE was also examined.</p><p><strong>Results: </strong>The decrease of glycemia in rats following the administration of the plant extract suggested that the studied extract possesses antidiabetic effect. The extract of S. hispanica produced hypolipidemic effect with a significant lowering effect on plasma total cholesterol levels and increased on HDL-cholesterol levels. SHSAE was also able to enhance glucose tolerance using OGTT. Moreover, SHSAE possesses a potential antioxidant effect in vitro.</p><p><strong>Conclusion: </strong>In conclusion, this study demonstrates the antihyperglycemic and antilipidemic effects of SHSAE in rats.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"20 1","pages":"60-66"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38814166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Monosubstituted Coumarins Inhibit Epinephrine-induced Platelet Aggregation. 单取代香豆素抑制肾上腺素诱导的血小板聚集。
Q2 Medicine Pub Date : 2022-01-01 DOI: 10.2174/1871525719666210427132808
Fausto Alejandro Jiménez-Orozco, Sergio Galicia-Zapatero, Edgar López-López, José L Medina-Franco, Fernando León Cedeño, Mirthala Flores-García, Ana María Mejia-Domínguez, Aurora de la Peña-Díaz

Aim: The aim of this study was to evaluate the in vitro effect of coumarin and 15 monosubstituted derivatives on the inhibition of human platelet aggregation induced by various proaggregatory agonists, particularly by epinephrine.

Background: The emergence of residual platelet reactivity during the use of conventional antiplatelet agents (acetylsalicylic acid and clopidogrel) is one of the main causes of double therapy´s therapeutic failure. Platelet adrenoceptors participate in residual platelet reactivity. Therefore, it is necessary to develop new antiplatelet agents that inhibit epinephrine-induced platelet aggregation as a new therapeutic strategy. Information on the antiplatelet activity of coumarins in inhibiting epinephrine-induced aggregation is limited.

Objective: The objective of this study was to establish the structure-activity relationship (SAR) of coumarin derivatives with hydroxy, methoxy, and acetoxy groups in different positions of the coumarin nucleus to identify the most active molecules. Moreover, this study aimed to use in silico studies to suggest potential drug targets to which the molecules bind to produce antiplatelet effects.

Methods: The platelet aggregation was performed using a Lumi-aggregometer; the inhibitory activity of 16 compounds were evaluated by inducing the aggregation of human platelets (250 × 103/μl) with epinephrine (10 μM), collagen (2 μg/ml) or ADP (10 μM). The aggregation of control platelets was considered 100% of the response for each pro-aggregatory agonist.

Results: Eleven molecules inhibited epinephrine-induced aggregation, with 3-acetoxycoumarin and 7-methoxycoumarin being the most active. Only coumarin inhibited collagen-induced platelet aggregation, but no molecule showed activity when using ADP as an inducer.

Conclusions: In silico studies suggest that most active molecules might have antagonistic interactions in the α2 and β2 adrenoceptors. The antiplatelet actions of these coumarins have the potential to reduce residual platelet reactivity and thus contribute to the development of future treatments for patients who do not respond adequately to conventional agents.

目的:本研究的目的是评价香豆素及其15种单取代衍生物在体外对各种促血小板聚集激动剂(尤其是肾上腺素)诱导的人血小板聚集的抑制作用。背景:在使用常规抗血小板药物(乙酰水杨酸和氯吡格雷)时出现残留的血小板反应性是双重治疗失败的主要原因之一。血小板肾上腺素受体参与残余血小板反应性。因此,有必要开发新的抗血小板药物,抑制肾上腺素诱导的血小板聚集,作为一种新的治疗策略。有关香豆素抑制肾上腺素诱导的血小板聚集的抗血小板活性的信息是有限的。目的:建立香豆素衍生物中羟基、甲氧基和乙氧基在香豆素核不同位置的构效关系,以鉴定活性最高的分子。此外,本研究旨在利用计算机研究提示分子结合产生抗血小板作用的潜在药物靶点。方法:采用lumi聚集仪进行血小板聚集;采用肾上腺素(10 μM)、胶原蛋白(2 μg/ml)或ADP (10 μM)诱导人血小板(250 × 103/μl)聚集的方法评价16种化合物的抑制活性。对照血小板的聚集被认为是每种促聚集激动剂应答的100%。结果:11种分子抑制肾上腺素诱导的聚集,其中3-乙酰氧基香豆素和7-甲氧基香豆素活性最强。只有香豆素对胶原诱导的血小板聚集有抑制作用,而以ADP为诱导剂时,没有分子显示出活性。结论:计算机研究表明,大多数活性分子可能在α2和β2肾上腺素受体中具有拮抗作用。这些香豆素的抗血小板作用具有降低残余血小板反应性的潜力,因此有助于开发对传统药物反应不充分的患者的未来治疗方法。
{"title":"Monosubstituted Coumarins Inhibit Epinephrine-induced Platelet Aggregation.","authors":"Fausto Alejandro Jiménez-Orozco,&nbsp;Sergio Galicia-Zapatero,&nbsp;Edgar López-López,&nbsp;José L Medina-Franco,&nbsp;Fernando León Cedeño,&nbsp;Mirthala Flores-García,&nbsp;Ana María Mejia-Domínguez,&nbsp;Aurora de la Peña-Díaz","doi":"10.2174/1871525719666210427132808","DOIUrl":"https://doi.org/10.2174/1871525719666210427132808","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to evaluate the in vitro effect of coumarin and 15 monosubstituted derivatives on the inhibition of human platelet aggregation induced by various proaggregatory agonists, particularly by epinephrine.</p><p><strong>Background: </strong>The emergence of residual platelet reactivity during the use of conventional antiplatelet agents (acetylsalicylic acid and clopidogrel) is one of the main causes of double therapy´s therapeutic failure. Platelet adrenoceptors participate in residual platelet reactivity. Therefore, it is necessary to develop new antiplatelet agents that inhibit epinephrine-induced platelet aggregation as a new therapeutic strategy. Information on the antiplatelet activity of coumarins in inhibiting epinephrine-induced aggregation is limited.</p><p><strong>Objective: </strong>The objective of this study was to establish the structure-activity relationship (SAR) of coumarin derivatives with hydroxy, methoxy, and acetoxy groups in different positions of the coumarin nucleus to identify the most active molecules. Moreover, this study aimed to use in silico studies to suggest potential drug targets to which the molecules bind to produce antiplatelet effects.</p><p><strong>Methods: </strong>The platelet aggregation was performed using a Lumi-aggregometer; the inhibitory activity of 16 compounds were evaluated by inducing the aggregation of human platelets (250 × 103/μl) with epinephrine (10 μM), collagen (2 μg/ml) or ADP (10 μM). The aggregation of control platelets was considered 100% of the response for each pro-aggregatory agonist.</p><p><strong>Results: </strong>Eleven molecules inhibited epinephrine-induced aggregation, with 3-acetoxycoumarin and 7-methoxycoumarin being the most active. Only coumarin inhibited collagen-induced platelet aggregation, but no molecule showed activity when using ADP as an inducer.</p><p><strong>Conclusions: </strong>In silico studies suggest that most active molecules might have antagonistic interactions in the α2 and β2 adrenoceptors. The antiplatelet actions of these coumarins have the potential to reduce residual platelet reactivity and thus contribute to the development of future treatments for patients who do not respond adequately to conventional agents.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"20 1","pages":"43-51"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/4d/CHAMC-20-43.PMC9127734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38914783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Cardioprotective Role of Theobroma cacao against Isoproterenol-Induced Acute Myocardial Injury. 可可对异丙肾上腺素诱导的急性心肌损伤的心脏保护作用。
Q2 Medicine Pub Date : 2022-01-01 DOI: 10.2174/1871525718999200917114954
Justin Atiang Beshel, Favour Nyoh Beshel, Justina Nwandimma Nwangwa, Idara Asuquo Okon, Clement Ikani Ejim, Daniel Udofia Owu

Background: Antioxidants are beneficial in myocardial infarction (MI). It is suggestive that Theobroma cacao (TC) with rich antioxidant properties can be of health benefits in myocardial injury.

Aim: The study investigated the effect of Theobroma cacao on cardioprotection in isoproterenol-induced myocardial infarction in rats.

Material and methods: Male Wistar rats divided into four groups of 6 rats were used for the study. In group 1, 0.9% normal saline placebo was administered via oral gavage to the control. Group 2 was the MI induced group that was given 100 mg/kg body weight isoproterenol subcutaneously twice at an interval of 24 hours. Group 3 was administered TC for 2 weeks at 100 mg/kg bodyweight via the oral route. Group 4 was pretreated with TC (100 mg/kg) via oral route for 2 weeks, immediately followed by the administration of 100 mg/kg body weight isoproterenol subcutaneously twice at an interval of 24 hours. The rats were sacrificed using chloroform anesthesia, and blood samples collected via cardiac puncture. The serum was analyzed for troponin level, lactate dehydrogenase (LDH), and malondialdehyde (MDA) level.

Results: The serum troponin, LDH, and MDA levels were found to be significantly (p<0.01) increased in the MI group compared with the control. Pretreatment with TC before MI induction significantly (p<0.01) prevented increased serum troponin, LDH, and MDA levels when compared with the MI group. There was also a significant (p<0.01) decrease in MDA in the TC group compared with the control.

Conclusion: These results suggest that Theobroma cacao protects against isoproterenol-induced myocardial injury, possibly by preventing oxidative stress and consequent lipid peroxidation.

背景:抗氧化剂对心肌梗死(MI)有益。提示可可可可具有丰富的抗氧化特性,对心肌损伤有一定的健康益处。目的:研究可可对异丙肾上腺素所致大鼠心肌梗死的保护作用。材料与方法:雄性Wistar大鼠分为4组,每组6只。第1组给予0.9%生理盐水安慰剂灌胃。第2组为心肌梗死诱导组,每隔24小时皮下注射异丙肾上腺素100 mg/kg体重2次。第3组给予100 mg/kg体重口服TC 2周。第4组小鼠口服TC (100 mg/kg)预处理2周,随后立即皮下注射异丙肾上腺素100 mg/kg体重,间隔24小时皮下注射2次。采用氯仿麻醉处死大鼠,穿刺取血。分析血清肌钙蛋白水平、乳酸脱氢酶(LDH)和丙二醛(MDA)水平。结果:血清肌钙蛋白、乳酸脱氢酶和丙二醛水平显著升高。结论:可可对异丙肾上腺素引起的心肌损伤具有保护作用,可能是通过防止氧化应激和由此引起的脂质过氧化作用。
{"title":"Cardioprotective Role of <i>Theobroma cacao</i> against Isoproterenol-Induced Acute Myocardial Injury.","authors":"Justin Atiang Beshel,&nbsp;Favour Nyoh Beshel,&nbsp;Justina Nwandimma Nwangwa,&nbsp;Idara Asuquo Okon,&nbsp;Clement Ikani Ejim,&nbsp;Daniel Udofia Owu","doi":"10.2174/1871525718999200917114954","DOIUrl":"https://doi.org/10.2174/1871525718999200917114954","url":null,"abstract":"<p><strong>Background: </strong>Antioxidants are beneficial in myocardial infarction (MI). It is suggestive that Theobroma cacao (TC) with rich antioxidant properties can be of health benefits in myocardial injury.</p><p><strong>Aim: </strong>The study investigated the effect of Theobroma cacao on cardioprotection in isoproterenol-induced myocardial infarction in rats.</p><p><strong>Material and methods: </strong>Male Wistar rats divided into four groups of 6 rats were used for the study. In group 1, 0.9% normal saline placebo was administered via oral gavage to the control. Group 2 was the MI induced group that was given 100 mg/kg body weight isoproterenol subcutaneously twice at an interval of 24 hours. Group 3 was administered TC for 2 weeks at 100 mg/kg bodyweight via the oral route. Group 4 was pretreated with TC (100 mg/kg) via oral route for 2 weeks, immediately followed by the administration of 100 mg/kg body weight isoproterenol subcutaneously twice at an interval of 24 hours. The rats were sacrificed using chloroform anesthesia, and blood samples collected via cardiac puncture. The serum was analyzed for troponin level, lactate dehydrogenase (LDH), and malondialdehyde (MDA) level.</p><p><strong>Results: </strong>The serum troponin, LDH, and MDA levels were found to be significantly (p<0.01) increased in the MI group compared with the control. Pretreatment with TC before MI induction significantly (p<0.01) prevented increased serum troponin, LDH, and MDA levels when compared with the MI group. There was also a significant (p<0.01) decrease in MDA in the TC group compared with the control.</p><p><strong>Conclusion: </strong>These results suggest that Theobroma cacao protects against isoproterenol-induced myocardial injury, possibly by preventing oxidative stress and consequent lipid peroxidation.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"20 1","pages":"75-80"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38388186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Meet the Editorial Board Member 与编辑委员会成员见面
Q2 Medicine Pub Date : 2021-09-01 DOI: 10.2174/187152571902211103154646
P. Baraldi
{"title":"Meet the Editorial Board Member","authors":"P. Baraldi","doi":"10.2174/187152571902211103154646","DOIUrl":"https://doi.org/10.2174/187152571902211103154646","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68037967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2021 药物化学中的心血管和血液制剂,2021
Q2 Medicine Pub Date : 2021-01-31 DOI: 10.2174/187152571901210310114849
Dejia Li
{"title":"Cardiovascular & Hematological Agents in Medicinal Chemistry, 2021","authors":"Dejia Li","doi":"10.2174/187152571901210310114849","DOIUrl":"https://doi.org/10.2174/187152571901210310114849","url":null,"abstract":"","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"100 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82436480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
An In Silico Approach Towards Investigation of Possible Effects of Essential Oils Constituents on Receptors Involved in Cardiovascular Diseases (CVD) and Associated Risk Factors (Diabetes Mellitus and Hyperlipidemia). 用计算机方法研究精油成分对心血管疾病(CVD)及相关危险因素(糖尿病和高脂血症)相关受体的可能影响。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871524920666200510013039
Azadeh Hamedi, Amirhossein Sakhteman, Seyed Mahmoud Moheimani

Aim: Aromatherapy products, hydrosol beverages and distillates containing essential oils are widely used for cardiovascular conditions. Investigation of the possible activity of their major constituents with the cardiovascular-related receptors may lead to developing new therapeutics. It also may prevent unwanted side effects and drug-herb interactions.

Materials and methods: A list of 243 volatile molecules (mainly monoterpene and sesquiterpene) was prepared from a literature survey in Scopus and PubMed (2000-2019) on hydrosols and essential oils which are used for Cardiovascular Diseases (CVD) and its risk factors (diabetes mellitus and hyperlipidemia). The PDB files of the receptors (229 native PDB files) included alpha-glucosidase, angiotensin- converting enzymes, beta-2 adrenergic receptor, glucocorticoid, HMG-CoA reductase, insulin, mineralocorticoid, potassium channel receptors and peroxisome proliferator-activated receptoralpha, were downloaded from Protein Data Bank. An in silico study using AutoDock 4.2 and Vina in parallel mode was performed to investigate possible interaction of the molecules with the receptors. Drug likeliness of the most active molecules was investigated using DruLiTo software.

Results: Spathulenol, bisabolol oxide A, bisabolone oxide, bergapten, bergamotene, dill apiole, pcymene, methyl jasmonate, pinocarveol, intermedeol, α-muurolol, S-camphor, ficusin, selinen-4-ol, iso-dihydrocarveol acetate, 3-thujanone, linanool oxide and cadinol isomers made a better interaction with some of the named receptors. All of the named molecules had an acceptable dug likeliness except for α-bergamotene. In addition, all of the named molecules had the ability to pass the bloodbrain barrier and it is possible to produce unwanted side effects.

Conclusion: Some ingredients of essential oils might be active on cardiovascular-related receptors.

目的:芳香疗法产品、纯露饮料和含有精油的馏分物被广泛用于心血管疾病。研究其主要成分与心血管相关受体的可能活性可能会导致开发新的治疗方法。它还可以防止不必要的副作用和药物-草药相互作用。材料与方法:通过查阅Scopus和PubMed(2000-2019)的文献,编制了243种用于心血管疾病(CVD)及其危险因素(糖尿病和高脂血症)的水溶胶和精油挥发性分子(主要是单萜烯和倍半萜烯)清单。从蛋白质数据库下载α -葡萄糖苷酶、血管紧张素转换酶、β -2肾上腺素能受体、糖皮质激素、HMG-CoA还原酶、胰岛素、矿化皮质激素、钾通道受体和过氧化物酶体增殖激活受体α等受体的PDB文件(共229个)。利用AutoDock 4.2和Vina在并行模式下进行了一项计算机研究,以研究分子与受体可能的相互作用。利用DruLiTo软件对最具活性分子的药物可能性进行研究。结果:Spathulenol, bisabolol oxide A, bisabolone oxide, bergapten,佛手柑烯,莳萝酚,pcymene,茉莉酸甲酯,pinocarveol,中间体,α- muurorol, S-camphor, ficusin, selinen-4-ol, iso-dihydrocarveol acetate, 3-thujanone, linanool oxide和cadinol异构体与一些命名受体有较好的相互作用。除α-佛手柑烯外,所有命名的分子都具有可接受的挖掘可能性。此外,所有命名的分子都具有通过血脑屏障的能力,并且有可能产生不必要的副作用。结论:精油的某些成分可能对心血管相关受体有活性。
{"title":"An In Silico Approach Towards Investigation of Possible Effects of Essential Oils Constituents on Receptors Involved in Cardiovascular Diseases (CVD) and Associated Risk Factors (Diabetes Mellitus and Hyperlipidemia).","authors":"Azadeh Hamedi,&nbsp;Amirhossein Sakhteman,&nbsp;Seyed Mahmoud Moheimani","doi":"10.2174/1871524920666200510013039","DOIUrl":"https://doi.org/10.2174/1871524920666200510013039","url":null,"abstract":"<p><strong>Aim: </strong>Aromatherapy products, hydrosol beverages and distillates containing essential oils are widely used for cardiovascular conditions. Investigation of the possible activity of their major constituents with the cardiovascular-related receptors may lead to developing new therapeutics. It also may prevent unwanted side effects and drug-herb interactions.</p><p><strong>Materials and methods: </strong>A list of 243 volatile molecules (mainly monoterpene and sesquiterpene) was prepared from a literature survey in Scopus and PubMed (2000-2019) on hydrosols and essential oils which are used for Cardiovascular Diseases (CVD) and its risk factors (diabetes mellitus and hyperlipidemia). The PDB files of the receptors (229 native PDB files) included alpha-glucosidase, angiotensin- converting enzymes, beta-2 adrenergic receptor, glucocorticoid, HMG-CoA reductase, insulin, mineralocorticoid, potassium channel receptors and peroxisome proliferator-activated receptoralpha, were downloaded from Protein Data Bank. An in silico study using AutoDock 4.2 and Vina in parallel mode was performed to investigate possible interaction of the molecules with the receptors. Drug likeliness of the most active molecules was investigated using DruLiTo software.</p><p><strong>Results: </strong>Spathulenol, bisabolol oxide A, bisabolone oxide, bergapten, bergamotene, dill apiole, pcymene, methyl jasmonate, pinocarveol, intermedeol, α-muurolol, S-camphor, ficusin, selinen-4-ol, iso-dihydrocarveol acetate, 3-thujanone, linanool oxide and cadinol isomers made a better interaction with some of the named receptors. All of the named molecules had an acceptable dug likeliness except for α-bergamotene. In addition, all of the named molecules had the ability to pass the bloodbrain barrier and it is possible to produce unwanted side effects.</p><p><strong>Conclusion: </strong>Some ingredients of essential oils might be active on cardiovascular-related receptors.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"19 1","pages":"32-42"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37915909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A DNA Repair Pathway Polymorphism (rs25487) and Angiographically Proven Coronary Artery Patients in a Population of Southern Iran. 伊朗南部人群中DNA修复通路多态性(rs25487)和血管造影证实的冠状动脉患者
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871525718666200805113813
Seyed M Hoseini, Mahdi Bijanzadeh, Seyed M Seyedian

Background: Coronary Artery Disease (CAD), which is a multifactorial genetic disease, is known as one of the most common causes of death worldwide. In this regard, X-ray Repair Cross-Complementing group 1 (XRCC1), a DNA repair protein involved in Single-Strand Breaks (SSBs), and Base Excision Repair (BER) pathways have been reported to be responsible for the efficient repair of single strand breaks and damaged bases in DNA.

Objectives: In the current study, we analyzed Arg399Gln (rs25487), which is one of the most common polymorphisms of XRCC1 gene that might be associated with the increased risk for CAD.

Methods: This case-control study was performed to investigate the relationship between this polymorphism and CAD development. In this study, 290 patients and 216 controls were diagnosed by cardiac angiography and then screened for the above-mentioned polymorphism using Restriction Fragment Length Polymorphisms (RFLP) method.

Results: The frequency of the GA genotype of XRCC1 Arg399Gln (rs25487) was significantly higher in CAD patients compared to the controls (p=0.002, OR: 1.21, 95% CI: 1.06-1.37). Moreover, its dominant mode (AA + GA) genotype had a 1.851-fold increase in the risk of CAD (p = 0.005).

Conclusion: Our findings demonstrated that Arg399Gln polymorphism of XRCC1 (rs25487) has a significant relationship with CAD and also plays a probable predisposing role in that. Our results support the role of DNA damages and the malfunctions of DNA repair system in the patients with CAD.

背景:冠状动脉疾病(CAD)是一种多因素遗传性疾病,是世界上最常见的死亡原因之一。在这方面,x射线修复交叉互补组1 (XRCC1)是一种参与单链断裂(SSBs)和碱基切除修复(BER)途径的DNA修复蛋白,据报道,它负责DNA单链断裂和受损碱基的有效修复。目的:在本研究中,我们分析了Arg399Gln (rs25487),这是XRCC1基因最常见的多态性之一,可能与CAD风险增加有关。方法:采用病例对照研究,探讨该多态性与CAD发展的关系。在本研究中,290例患者和216例对照者通过心脏血管造影诊断,然后使用限制性片段长度多态性(RFLP)方法筛选上述多态性。结果:XRCC1 Arg399Gln (rs25487) GA基因型在CAD患者中的出现频率明显高于对照组(p=0.002, OR: 1.21, 95% CI: 1.06-1.37)。其优势模式(AA + GA)基因型的冠心病风险增加1.851倍(p = 0.005)。结论:我们的研究结果表明,XRCC1 (rs25487)的Arg399Gln多态性与CAD有显著关系,并可能在CAD中起易感作用。我们的研究结果支持DNA损伤和DNA修复系统故障在冠心病患者中的作用。
{"title":"A DNA Repair Pathway Polymorphism (rs25487) and Angiographically Proven Coronary Artery Patients in a Population of Southern Iran.","authors":"Seyed M Hoseini,&nbsp;Mahdi Bijanzadeh,&nbsp;Seyed M Seyedian","doi":"10.2174/1871525718666200805113813","DOIUrl":"https://doi.org/10.2174/1871525718666200805113813","url":null,"abstract":"<p><strong>Background: </strong>Coronary Artery Disease (CAD), which is a multifactorial genetic disease, is known as one of the most common causes of death worldwide. In this regard, X-ray Repair Cross-Complementing group 1 (XRCC1), a DNA repair protein involved in Single-Strand Breaks (SSBs), and Base Excision Repair (BER) pathways have been reported to be responsible for the efficient repair of single strand breaks and damaged bases in DNA.</p><p><strong>Objectives: </strong>In the current study, we analyzed Arg399Gln (rs25487), which is one of the most common polymorphisms of XRCC1 gene that might be associated with the increased risk for CAD.</p><p><strong>Methods: </strong>This case-control study was performed to investigate the relationship between this polymorphism and CAD development. In this study, 290 patients and 216 controls were diagnosed by cardiac angiography and then screened for the above-mentioned polymorphism using Restriction Fragment Length Polymorphisms (RFLP) method.</p><p><strong>Results: </strong>The frequency of the GA genotype of XRCC1 Arg399Gln (rs25487) was significantly higher in CAD patients compared to the controls (p=0.002, OR: 1.21, 95% CI: 1.06-1.37). Moreover, its dominant mode (AA + GA) genotype had a 1.851-fold increase in the risk of CAD (p = 0.005).</p><p><strong>Conclusion: </strong>Our findings demonstrated that Arg399Gln polymorphism of XRCC1 (rs25487) has a significant relationship with CAD and also plays a probable predisposing role in that. Our results support the role of DNA damages and the malfunctions of DNA repair system in the patients with CAD.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"19 1","pages":"76-82"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38250204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from Scorzanera Undulata Tubers in Streptozotocin-Induced Diabetic Rats. 蛇尾草茎水提物对链脲佐菌素诱导的糖尿病大鼠的降血脂、抗氧化和心脏保护作用。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871525718666201013152449
Mohammed Ajebli, Ayoub Amssayef, Mohamed Eddouks

Aims: This study aimed to assess the effect of Scorzanera undulata on plasma lipid profile.

Background: Scorzanera undulata (S. undulata) is a medicinal plant popularly used in the Moroccan pharmacopeia as traditional medicine, particularly to treat diabetes mellitus.

Objective: The purpose of this study was to explore the effects of aqueous extract of Scorzanera undulata tubers (AERSU) on lipid profile and atherogenic indices in Wistar rats. Biochemical parameters such as Total Cholesterol (TC), triglycerides (TG), and low-and high-density lipoproteins-cholesterol (LDL and HDL) were assessed. Furthermore, the in vitro antioxidant activity of AERSU was also evaluated.

Methods: The effect of tubers aqueous extract (AERSU) of S. undulata (20 mg/kg) on plasma lipid profile was investigated in normal and streptozotocin (STZ)-induced diabetic rats. The aqueous extract was tested for its in vitro antioxidant activity. Besides, cardiovascular parameters were estimated.

Results: Treatment with AERSU significantly improved the weight in diabetic rats and decreased plasma cholesterol, triglycerides, and LDL lipoproteins levels. Furthermore, the extract had a favorable impact on the Atherogenic Index (AI) and Coronary Risk Index (CRI). In addition, AERSU seems to possess a potent in vitro antioxidant activity.

Conclusion: The study demonstrates that aqueous Scorzanera undulate extract exhibits antidyslipidemic and antioxidant activities.

目的:本研究旨在探讨蛇尾草对血脂的影响。背景:荡浪形Scorzanera undulata (S. undulata)是一种药用植物,在摩洛哥药典中作为传统药物被广泛使用,特别是用于治疗糖尿病。目的:探讨山葵水提物(AERSU)对Wistar大鼠血脂及动脉粥样硬化指标的影响。评估生化参数,如总胆固醇(TC)、甘油三酯(TG)、低脂蛋白和高密度脂蛋白-胆固醇(LDL和HDL)。并对其体外抗氧化活性进行了评价。方法:采用链脲佐菌素(STZ)诱导的糖尿病大鼠和正常大鼠,研究了山楂块茎水提物(AERSU) (20 mg/kg)对糖尿病大鼠血脂的影响。测定了水提物的体外抗氧化活性。并对心血管参数进行估计。结果:AERSU治疗显著改善糖尿病大鼠体重,降低血浆胆固醇、甘油三酯和LDL脂蛋白水平。此外,提取物对动脉粥样硬化指数(AI)和冠状动脉危险指数(CRI)有良好的影响。此外,AERSU似乎具有强大的体外抗氧化活性。结论:波浪形鲉水提物具有抗血脂异常和抗氧化活性。
{"title":"Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from Scorzanera Undulata Tubers in Streptozotocin-Induced Diabetic Rats.","authors":"Mohammed Ajebli,&nbsp;Ayoub Amssayef,&nbsp;Mohamed Eddouks","doi":"10.2174/1871525718666201013152449","DOIUrl":"https://doi.org/10.2174/1871525718666201013152449","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to assess the effect of Scorzanera undulata on plasma lipid profile.</p><p><strong>Background: </strong>Scorzanera undulata (S. undulata) is a medicinal plant popularly used in the Moroccan pharmacopeia as traditional medicine, particularly to treat diabetes mellitus.</p><p><strong>Objective: </strong>The purpose of this study was to explore the effects of aqueous extract of Scorzanera undulata tubers (AERSU) on lipid profile and atherogenic indices in Wistar rats. Biochemical parameters such as Total Cholesterol (TC), triglycerides (TG), and low-and high-density lipoproteins-cholesterol (LDL and HDL) were assessed. Furthermore, the in vitro antioxidant activity of AERSU was also evaluated.</p><p><strong>Methods: </strong>The effect of tubers aqueous extract (AERSU) of S. undulata (20 mg/kg) on plasma lipid profile was investigated in normal and streptozotocin (STZ)-induced diabetic rats. The aqueous extract was tested for its in vitro antioxidant activity. Besides, cardiovascular parameters were estimated.</p><p><strong>Results: </strong>Treatment with AERSU significantly improved the weight in diabetic rats and decreased plasma cholesterol, triglycerides, and LDL lipoproteins levels. Furthermore, the extract had a favorable impact on the Atherogenic Index (AI) and Coronary Risk Index (CRI). In addition, AERSU seems to possess a potent in vitro antioxidant activity.</p><p><strong>Conclusion: </strong>The study demonstrates that aqueous Scorzanera undulate extract exhibits antidyslipidemic and antioxidant activities.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"19 1","pages":"17-23"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38488824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS). sacubitil -缬沙坦改善心肾综合征贫血(CRS)。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871525718666200506095537
Nicolás R Robles, Rosa D Campillejo, Julian Valladares, Elena G de Vinuesa, Juan Villa, Guillermo Gervasini

Background and aims: Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the short-term effects of sacubitril- valsartan on the anemia of CRS.

Methods: The study group comprised 39 patients with HFrEF, who were followed-up for three months. The study is a retrospective analysis of clinical data. Data of 3 months' and baseline visits were recorded including plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin, pro-BNP, and albuminuria.

Results: In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101 ± 62 mg/day and 126 ± 59 mg/day at end. Mean hemoglobin increased from 12.2 ± 1.1 g/dl at baseline to 12.9 ± 1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI, 47.9-78.5%) at baseline and 38.4 (95%CI, 23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71 ± 1.0 to 2.48 ± 1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline 4.94 ± 0.60, three months visit 4.94 ± 0.61 mmol/l, p = 0.998).

Conclusion: Sacubitril-valsartan improves anemia in CRS patients. An improvement in serum cystatin levels was observed. Few untoward effects were detected. These findings should be confirmed in wider clinical trials.

背景和目的:贫血是心力衰竭和慢性肾脏疾病(CKD)的常见并发症。sacubitil -缬沙坦是一种治疗慢性心力衰竭伴射血分数降低(HFrEF)的新疗法。我们评估了苏比里尔-缬沙坦治疗CRS贫血的短期效果。方法:研究组39例HFrEF患者,随访3个月。该研究是对临床资料的回顾性分析。记录3个月及基线就诊数据,包括血浆肌酐、肾小球滤过率、胱抑素C、血钾、血红蛋白、bnp前体和蛋白尿。结果:34例患者结束随访。基线时沙比替-缬沙坦平均剂量为101±62 mg/天,结束时为126±59 mg/天。平均血红蛋白从基线时的12.2±1.1 g/dl增加到12.9±1.0 g/dl (p = 0.001)。基线时贫血发生率为64.7% (95%CI, 47.9 ~ 78.5%),随访后为38.4% (95%CI, 23.9 ~ 55.0%) (p = 0.016)。血清胱抑素C水平由2.71±1.0 mg/l降至2.48±1.0 mg/l (p = 0.028)。血清K水平保持不变(基线4.94±0.60,3个月随访4.94±0.61 mmol/l, p = 0.998)。结论:沙司比利-缬沙坦可改善CRS患者贫血。观察到血清胱抑素水平的改善。几乎没有发现不良影响。这些发现应该在更广泛的临床试验中得到证实。
{"title":"Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS).","authors":"Nicolás R Robles,&nbsp;Rosa D Campillejo,&nbsp;Julian Valladares,&nbsp;Elena G de Vinuesa,&nbsp;Juan Villa,&nbsp;Guillermo Gervasini","doi":"10.2174/1871525718666200506095537","DOIUrl":"https://doi.org/10.2174/1871525718666200506095537","url":null,"abstract":"<p><strong>Background and aims: </strong>Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the short-term effects of sacubitril- valsartan on the anemia of CRS.</p><p><strong>Methods: </strong>The study group comprised 39 patients with HFrEF, who were followed-up for three months. The study is a retrospective analysis of clinical data. Data of 3 months' and baseline visits were recorded including plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin, pro-BNP, and albuminuria.</p><p><strong>Results: </strong>In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101 ± 62 mg/day and 126 ± 59 mg/day at end. Mean hemoglobin increased from 12.2 ± 1.1 g/dl at baseline to 12.9 ± 1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI, 47.9-78.5%) at baseline and 38.4 (95%CI, 23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71 ± 1.0 to 2.48 ± 1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline 4.94 ± 0.60, three months visit 4.94 ± 0.61 mmol/l, p = 0.998).</p><p><strong>Conclusion: </strong>Sacubitril-valsartan improves anemia in CRS patients. An improvement in serum cystatin levels was observed. Few untoward effects were detected. These findings should be confirmed in wider clinical trials.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"19 1","pages":"93-97"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37902387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Radioprotective Effect of Pioglitazone Against Genotoxicity Induced by Ionizing Radiation in Healthy Human Lymphocytes. 吡格列酮对正常人淋巴细胞电离辐射遗传毒性的辐射防护作用。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871525718666200525005231
Roya Kazemi, Seyed J Hosseinimehr

Objective: Pioglitazone (PG) is used to control high blood sugar in patients with type 2 diabetes mellitus. PG acts as a peroxisome proliferator-activated receptor γ agonist. In addition to the insulin-sensitizing effect, PG possesses anti-inflammatory effect. In this study, the protective effect of PG was evaluated against DNA damage induced by ionizing radiation in healthy human lymphocytes.

Methods: The microtubes containing human whole blood were treated with PG at various concentrations (1-50 μM) for three hours. Then, the blood samples were irradiated with X-ray. Lymphocytes were cultured for determining the frequency of micronuclei as a genotoxicity biomarker in binucleated lymphocytes.

Results: The mean percentage of micronuclei was significantly increased in human lymphocytes when exposed to IR, while it was decreased in lymphocytes pre-treated with PG. The maximum reduction in the frequency of micronuclei in irradiated lymphocytes was observed at 5 μM of PG treatment (48% decrease).

Conclusion: The anti-inflammatory property suggested the mechanism action of PG for protecting human lymphocytes against genotoxicity induced by ionizing radiation.

目的:应用吡格列酮(PG)控制2型糖尿病患者的高血糖。PG作为过氧化物酶体增殖物激活受体γ激动剂。PG除具有胰岛素增敏作用外,还具有抗炎作用。本研究评价了PG对电离辐射诱导的健康人淋巴细胞DNA损伤的保护作用。方法:用不同浓度PG (1 ~ 50 μM)处理含人全血的微管3 h。然后,用x射线照射血液样本。培养淋巴细胞,以确定微核作为遗传毒性生物标志物在双核淋巴细胞中的频率。结果:人淋巴细胞微核的平均百分比在红外照射下显著升高,而PG预处理后的淋巴细胞微核的平均百分比降低,在PG处理5 μM时,微核的频率降低幅度最大(降低48%)。结论:PG具有抗炎作用,具有保护人淋巴细胞免受电离辐射遗传毒性的作用机制。
{"title":"Radioprotective Effect of Pioglitazone Against Genotoxicity Induced by Ionizing Radiation in Healthy Human Lymphocytes.","authors":"Roya Kazemi,&nbsp;Seyed J Hosseinimehr","doi":"10.2174/1871525718666200525005231","DOIUrl":"https://doi.org/10.2174/1871525718666200525005231","url":null,"abstract":"<p><strong>Objective: </strong>Pioglitazone (PG) is used to control high blood sugar in patients with type 2 diabetes mellitus. PG acts as a peroxisome proliferator-activated receptor γ agonist. In addition to the insulin-sensitizing effect, PG possesses anti-inflammatory effect. In this study, the protective effect of PG was evaluated against DNA damage induced by ionizing radiation in healthy human lymphocytes.</p><p><strong>Methods: </strong>The microtubes containing human whole blood were treated with PG at various concentrations (1-50 μM) for three hours. Then, the blood samples were irradiated with X-ray. Lymphocytes were cultured for determining the frequency of micronuclei as a genotoxicity biomarker in binucleated lymphocytes.</p><p><strong>Results: </strong>The mean percentage of micronuclei was significantly increased in human lymphocytes when exposed to IR, while it was decreased in lymphocytes pre-treated with PG. The maximum reduction in the frequency of micronuclei in irradiated lymphocytes was observed at 5 μM of PG treatment (48% decrease).</p><p><strong>Conclusion: </strong>The anti-inflammatory property suggested the mechanism action of PG for protecting human lymphocytes against genotoxicity induced by ionizing radiation.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"19 1","pages":"72-75"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37972090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular and Hematological Agents in Medicinal Chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1